Comparison of Clinical Characterization and Therapeutic Strategies between Homozygous Familial Hypercholesterolemia and Heterozygous Familial Hypercholesterolemia
Aims: Homozygous Familial hypercholesterolemia (HoFH) is a rare genetic disease characterized by very high levels of low-density lipoprotein cholesterol (LDL-C). Owing to LDL receptor activity being completely or nearly all lost in HoFH, LDL-C levels greatly exceed normal levels, and are even higher than in heterozygous (HeFH), which can cause fatal cardiovascular disease even in infancy. The current study updates differences in clinical characterization, therapeutic strategies and cardiovascular outcomes between HoFH and HeFH.
Authors
- Kenta Sakaguchi
- Yumiko Kanzaki (ORCID: https://orcid.org/0000-0003-1228-1201)
- Masahito Michikura (ORCID: https://orcid.org/0000-0002-1258-8310)
- H Morita
- T F Fujisaka
- S Fujioka
- D Shishikura
- H K Kusumoto
- Mariko Harada-Shiba
Institutions
- Osaka University of Pharmaceutical Sciences (JP)
Publication Details
- Journal
- Journal of Atherosclerosis and Thrombosis
- Published
- 2026-01-01
- DOI
- https://doi.org/10.5551/jat.65959
- Citations
- 1
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 39.15